Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
10.33
-0.49 (-4.53%)
At close: Nov 20, 2024, 4:00 PM
10.43
+0.10 (0.97%)
Pre-market: Nov 21, 2024, 6:40 AM EST

Company Description

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.

Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.

The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn’s disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease.

It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy.

It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain.

The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Mesoblast Limited
Mesoblast logo
Country Australia
Founded 2004
Industry Biotechnology
Sector Healthcare
Employees 73
CEO Silviu Itescu

Contact Details

Address:
55 Collins Street, Level 38
Melbourne, VIC 3000
Australia
Phone 61 3 9639 6036
Website mesoblast.com

Stock Details

Ticker Symbol MESO
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency USD
CIK Code 0001345099
CUSIP Number 590717104
ISIN Number US5907174016
SIC Code 2836

Key Executives

Name Position
Dr. Paul J. Simmons BSc, Ph.D. Scientific Advisor to the Chief Executive Officer
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) Founder, Chief Executive Officer, MD, Chairman of Scientific Advisory Board and Executive Director
Dr. Eric A. Rose M.D. Chief Medical Officer and Executive Director
Andrew Chaponnel B.Com. Interim Chief Finance Officer
Peter T. Howard B.Sc., L.L.B., LLB (Hons) General Counsel and Corporate Executive
Geraldine Storton B.Sc., M.B.A., MMS Head of Regulatory Affairs and Quality Management
Justin Horst B.S. Head of Manufacturing
Dr. Fiona See Ph.D. Senior Vice President and Head of Translational Research
Niva Sivakumar B.Com., L.L.B. Joint Company Secretary
Paul Hughes BPHARM Joint Company Secretary

Latest SEC Filings

Date Type Title
Nov 18, 2024 6-K Report of foreign issuer
Nov 13, 2024 6-K Report of foreign issuer
Nov 1, 2024 6-K Report of foreign issuer
Oct 18, 2024 6-K Report of foreign issuer
Oct 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 1, 2024 6-K Report of foreign issuer
Aug 29, 2024 6-K Report of foreign issuer
Aug 29, 2024 20-F Annual and transition report of foreign private issuers
Aug 1, 2024 6-K Report of foreign issuer
Jul 25, 2024 6-K Report of foreign issuer